The Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response awarded a $79,947,200.00 Firm Fixed Price contract to Elusys Therapeutics Inc. for the manufacture and vendor managed inventory of Anthim (obiltoxaximab) 600mg/6ml for Injection, an FDA-approved anthrax antitoxin. The contract has a period of performance from August 6, 2021 through September 14, 2024, and includes options for additional manufacturing and delivery of finished drug product and bulk drug substance. The contractor will be responsible for manufacturing, warehousing, inventory management, and distribution of the anthrax antitoxin to replenish and sustain the Strategic National Stockpile. This sole source contract was awarded under FAR 6.302-3(a)(2)(i) and has no set-aside designation.
Generated 9/7/24, 9:50 AM